Testosterone and prostate safety: what TRAVERSE can—and cannot—reassure
TRAVERSE found low, similar prostate-event rates in carefully screened men. Review PSA changes, exclusions, monitoring, and why the trial is not a universal guarantee.

In carefully screened men with confirmed hypogonadism, TRAVERSE did not find significant differences in prostate cancer or major prostate events, but follow-up was limited and higher-risk men were excluded.
The prostate question needed a large randomized trial
Prostate tissue responds to androgens, which created a long-running concern that testosterone therapy might initiate or accelerate prostate cancer. Observational studies are difficult to interpret because treated and untreated men differ in screening, health, contraindications, and follow-up.
TRAVERSE enrolled more than 5,200 men with symptoms, two fasting testosterone values below 300 ng/dL, and cardiovascular disease or elevated cardiovascular risk. A prespecified prostate-safety analysis compared testosterone gel with placebo and used adjudicated clinical events rather than relying only on PSA changes.

Major prostate events were uncommon and similar
High-grade prostate cancer occurred in five testosterone participants and three placebo participants, a difference that was not statistically significant and had a wide confidence interval. Rates of any prostate cancer, acute urinary retention, invasive prostate procedures, biopsies, and new urinary-symptom medication also did not differ significantly.
These findings are reassuring for men resembling the trial population. They do not prove that testosterone prevents prostate disease or that lifetime risk is identical. Prostate cancers can develop slowly, and the average treatment exposure and follow-up were far shorter than the decades relevant to carcinogenesis.
Careful screening limits generalization
The trial excluded men with PSA above 3.0 ng/mL and those with severe lower urinary tract symptoms. Participants were evaluated before enrollment and monitored during treatment. A result in this selected population cannot be pasted onto a man with an unevaluated prostate nodule, markedly elevated PSA, known prostate cancer, or severe urinary obstruction.
The baseline average PSA was low. That context matters when a headline says prostate events were rare. Good selection and monitoring are part of the intervention, not background details that can be removed while keeping the same safety result.
PSA rose more with testosterone
TRAVERSE found a greater increase in PSA among testosterone-treated men even though adjudicated cancer rates were similar. PSA is prostate-specific, not cancer-specific; benign growth, inflammation, infection, ejaculation, instrumentation, and laboratory variation can affect it.
A rising PSA does not diagnose cancer, but it can trigger repeat testing or urologic evaluation. Endocrine guidance recommends discussing prostate-risk assessment and monitoring with appropriate men before treatment and reassessing during the first year. Shared decision-making should reflect age, family history, race, life expectancy, and personal priorities.

Symptoms still need attention
Weak stream, urgency, frequency, nighttime urination, and incomplete emptying can arise from benign prostate enlargement, bladder dysfunction, infection, diabetes, sleep apnea, medicines, or cancer. Testosterone should not be blamed automatically, but new or worsening symptoms should be reported rather than managed with an over-the-counter prostate supplement.
Inability to urinate, blood in the urine, fever with urinary symptoms, severe pelvic pain, or neurologic symptoms requires prompt care. A normal earlier PSA does not rule out every prostate problem, and testosterone monitoring does not replace routine age- and risk-appropriate evaluation.
How to use the evidence
For a properly diagnosed man who passes baseline evaluation, the randomized data offer meaningful short-term reassurance that major prostate events were not substantially increased. The finding is stronger than an uncontrolled clinic series and narrower than a lifelong safety guarantee.
Ask what baseline evaluation is planned, what PSA change would trigger repeat testing or referral, and how urinary symptoms will be tracked. The safest summary preserves the trial’s selection and monitoring: testosterone can be considered when indicated, while prostate risk remains an active part of care rather than a settled issue.
Monitoring can create benefits and burdens
More PSA testing can detect clinically important disease, but it can also lead to repeat blood work, imaging, biopsy, anxiety, and detection of cancers that might never have caused harm. Discussing those tradeoffs before testosterone begins helps prevent an abnormal result from becoming an unplanned decision made under pressure.
Keep prior PSA values and urinary symptom scores so a clinician can interpret the trajectory rather than one isolated number. Timing relative to infection, urinary retention, catheterization, cycling, and ejaculation may matter. Do not take antibiotics or stop testosterone solely to manipulate PSA without a medical plan.
Sources & further reading
This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.